1h Free Analyst Time
The Anti-CD20 monoclonal antibodies (mABs) market is forecasted to grow by USD 11425.15 mn during 2023-2028, accelerating at a CAGR of 10.31% during the forecast period. The report on the Anti-CD20 monoclonal antibodies (mABs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased use of combination therapies, high target affinity and specificity of Anti-CD20 mABs, and strong pipeline and recent approvals.
The Anti-CD20 monoclonal antibodies (mABs) market is segmented as below:
By Product
- Oncology
- Neurology
- Immunology
By Type
- First generation Anti-CD20 monoclonal antibody
- Second generation Anti-CD20 monoclonal antibody
- Third generation Anti-CD20 monoclonal antibody
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the Anti-CD20 monoclonal antibodies (mABs) market covers the following areas:
- Anti-CD20 monoclonal antibodies (mABs) market sizing
- Anti-CD20 monoclonal antibodies (mABs) market forecast
- Anti-CD20 monoclonal antibodies (mABs) market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global anti-cd20 monoclonal antibodies (mabs) market: Acrotech Biopharma Inc., Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing awareness about therapeutic areas.'
According to the report, one of the major drivers for this market is the increased use of combination therapies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acrotech Biopharma Inc.
- Amgen Inc.
- AstraZeneca Plc
- Celltrion Healthcare Co. Ltd.
- F. Hoffmann La Roche Ltd.
- Fosun International Ltd.
- Genmab AS
- IGM Biosciences Inc.
- JSC BIOCAD
- LFB SA
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Spectrum Pharmaceuticals Inc.
- TG Therapeutics Inc.
- United BioPharma Inc.
- ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.
